SKCN Jefferson Oncology Group Annual Meeting: Emerging Strategies in the Treatment of Colorectal Cancer - An Interactive Case Based Review

This active learning format will provide participants the opportunity to examine challenging clinical cases from multiple perspectives and gain an in depth understanding of how experienced healthcare providers approach difficult patient care decisions.

The meeting will review evolving strategies in total neoadjuvant chemotherapy for rectal cancer, describe the role of circulating tumor DNA in treatment decisions, discuss appropriate utilization of immunotherapy and targeted therapies in colorectal cancer, recognize the role of surgical management for patients with metastatic colorectal cancer, and identify the use of radiation therapy in rectal cancers. This meeting is designed to provide attendees to learn more about the options and advances in treating colorectal cancers.

Successful Completion

 To successfully complete this activity, the required evaluation must be completed no later than Wednesday, March 24, 2024. Thereafter, the evaluation will no longer be available and credits will not be issued. No refunds will be offered for failure to complete the required evaluation by the stated deadline.

Zoom log in information is available on the Course Content tab.

1. Review evolving strategies in total neoadjuvant chemotherapy for rectal cancer.
2. Recognize the indications and outcomes for immunotherapies and biologic therapies in colorectal cancer.
3. Identify the role of radiation therapy in the treatment of rectal cancer.
4. Describe the utility of circulating tumor DNA in the treatment of colorectal cancer.
5. Discuss surgical management for patients with metastatic colorectal cancer.

In support of improving patient care, Thomas Jefferson University is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: This educational activity is designated for a maximum of 2.25 AMA PRA Category 1 Credits ^TM . Physicians should only claim credit commensurate with the extent of their participation in the activity.

Other Healthcare Professionals: This educational activity is designated for 2.25 AMA PRA Category 1 Credit ^TM. Participants should claim only the credit commensurate with the extent of their participation in the activity. 

PA Patient Safety and Risk Credit: This education activity offers 2.25 PA Patient Safety and Risk credit. All sessions qualify.

Cancellation Policy

Requests for refunds must be submitted in writing and received in the Office of CPD two weeks prior to the start date of the course. There will be no refunds after this period.*  Cancellations notified before the two week time frame will incur a 25% administration fee (with a minimum of $20).  Registrants who fail to attend the conference are responsible for the entire fee.  All refunds will be processed after the conference.  The University reserves the right to cancel or postpone this course due to unforeseen circumstances.  In the event of cancellation or postponement, the University will refund registration fees, but is not responsible for related costs or expenses to participants, including cancellation fees assessed by hotels, airlines or travel agencies. 

*Registration fees will be refunded less a 15% administration fee to international conference registrants who are unable to secure a travel visa. Registrants must provide proof of visa denial. 

 Jefferson Release Policy

Jefferson may record/livestream/photograph this educational activity. These images/recordings, along with your name, may be used in Jefferson publications or on the Jefferson website. If you verbally submit any questions for Q&A sessions, you are agreeing to be recorded and to have that recording available in enduring materials. Once photographed, filmed, recorded, or videotaped, you waive the right of inspection or approval to which such images/recordings may be put and Jefferson has the right to use, publish, reproduce, modify, adapt, and distribute at any time in any manner or medium.

Jefferson HIPAA Policy

As an attendee of this educational activity hosted by Thomas Jefferson University, Jefferson University Physicians, and Thomas Jefferson University Hospitals, Inc. (collectively 'Jefferson'), you may gain access to certain proprietary information ('Confidential Information'), including Protected Health Information ('PHI').

By participating in this educational activity, you agree to maintain the confidentiality of all Confidential Information, including all PHI, obtained from any source. You also agree to take all necessary steps to protect such Confidential Information and shall not directly or indirectly disclose or use it in any manner or for any reason, other than as necessary to complete the educational activity. Further, you agree not to take photographs, record in any manner or otherwise reproduce any such Confidential Information. You understand that any unauthorized use or disclosure of Confidential Information may result in possible legal action against you by Jefferson whose confidentiality is breached.

Mitigation of Relevant Financial Relationships

Thomas Jefferson University adheres to the Standards for Integrity and Independence in Accredited Continuing Education and the policies that supplement the Standards.

All planners, faculty, and others in control of educational content are required to disclose any relevant financial relationships with ACCME defined ineligible companies within the past 24 months. Any conflicts of interests have been mitigated prior to this educational activity. Such disclosures will be available prior to the start of the activity. Jefferson conflict of interest mitigation process may result in changes to the program agenda.

Off-Label/Investigational Use
All faculty/presenters/authors at Thomas Jefferson University sponsored events are required to disclose whether or not their content contains information of commercial products/devices that are unlabeled for use or investigational uses of products not yet approved. Product(s) is/are not included in the labeling approved by the U.S. FDA for the treatment of disease(s).

Content Disclaimer
The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices or Thomas Jefferson University.

It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in this activity are believed to be accurate. However, participants are urged to consult all available data on products and procedures before using them in clinical practice.

Member Information

Role in activity

Nature of Relationship(s) / Name of Ineligible Company(s)

Rita S Axelrod, MD
Professor, Medical Oncology
Thomas Jefferson University
Philadelphia, PA

Co-Director, Faculty

Nothing to disclose

Steven J Cohen, MD
Medical Director, Asplundh Cancer Pavilion
Abington Jefferson Health
Willow Grove, PA

Co-Director, Faculty

Nothing to disclose

James Posey, MD
Medical Oncologist
Thomas Jefferson University
Philadelphia, PA

Co-Director, Faculty

Nothing to disclose

Pramila R Anne, MD
Associate Professor, Director of Clinical Operations, Department of Radiation Oncology
Thomas Jefferson University
Philadelphia, PA

Faculty

Nothing to disclose

Babar Bashir, MD, FACP
Assistant Professor
Thomas Jefferson University Hospital
Philadelphia, PA

Faculty

Grant or research support-Amgen, Inc.|Grant or research support-Bicycle Therapeutics|Grant or research support-Artios Pharma|Grant or research support-Elucida Oncology|Grant or research support-Gritstone Bio|Grant or research support-Ikena Oncology|Grant or research support-Jazz Pharmaceuticals|Grant or research support-KAHR Medical|Grant or research support-Lyell Immunopharma|Grant or research support-Merck (Any division)|Grant or research support-Pionyr Immunopharma|Grant or research support-RASCAL Therapeutics

Eduardo E Fernandez, MD
Oncologist
Sidney Kimmel Cancer Center
Mount Laurel, NJ

Faculty

Nothing to disclose

William K Kelly, DO
Director of Solid Tumor Oncology
Thomas Jefferson University
Philadelphia, PA

Faculty

Non-Clinical Exception

John Leighton Jr., MD
Division Chair -- Medical Oncology/Hematology
Einstein Healthcare Network
Huntingdon Valley, PA

Faculty

Nothing to disclose

Daniel Lin, MD
Assistant Professor
Thomas Jefferson University Hospital
Philadelphia, PA

Faculty

Nothing to disclose

John Marks, MD, FACS, FASCRS
Chief of Colorectal Surgery
Main Line Health System
Wynnewood, PA

Faculty

Nothing to disclose

Ankur R Parikh, DO
Jefferson Health
Ambler, PA

Faculty

Consulting Fee-Foundation Medicine, Inc.|Consulting Fee-Bayer (Any division)

Benjamin R Phillips, MD
Chief, Division of Colorectal Surgery
Thomas Jefferson University Hospital
Philadelphia, PA

Faculty

Nothing to disclose

Barbara Fischer, BSN, RN, OCN
Outreach Program Manager
Jefferson University Hospital
Philadelphia, PA

Nurse Planner

Nothing to disclose

Kathleen O'Doherty, RN, BSN, OCN
Nursing Care Navigator: Oncology Outreach
Sidney Kimmel Cancer Center - Jefferson Health
Ardmore, PA

Nurse Planner

Nothing to disclose

Thursday, February 29, 2024

This educational activity received no commercial or in-kind support.

To exhibit at this virtual event, please contact [email protected]

• Exhibitor is not providing commercial support for this educational activity. Exhibitor is purchasing exhibit space.
• Exhibits are intended for informational purposes, products should not be sold through the exhibit hall.
• TJU and the exhibitor acknowledge and agree that the exhibitor may be subject to Section 6002 of the Affordable Care Act, which added Section 1128G to the Social Security Act, and its implementing regulations codified in 42 CFR 402 &403 (Collectively the Sunshine Act). Exhibiting companies are solely responsible for collecting any information about actions within their virtual exhibit space that constitutes a payment or transfer of value to a covered participant, which is required to reported under the Sunshine Act.
• Exhibitors may observe educational sessions but must refrain from participating in the activity.
• No recordings of the scientific sessions on behalf of the exhibitor's company is permitted.

• Prior to the deadline of February 1, 2024 a refund will be given minus a 10% administration fee.
• After February 1, 2024 no refund will be given.
• Exhibitors who are absent from the conference will not receive a refund.
• Exhibit cancellations must be made in writing. Send cancellation notice to [email protected] and include name of activity in subject line.